X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ALXO

Closed

Alx Oncology Holdings 

0.4333
+0.0182 (+4.38%)
Last Update: 01 Jul 2025 23:10:00
Yesterday: 0.4151
Day's Range: 0.4103 - 0.4575
Send
When Written:
 
4.52
Alx Oncology Holdings is a clinical-stage biopharmaceutical company that is focused on developing cancer immunotherapies. The company's lead product candidate, ALX148, is a first-in-class monoclonal antibody that targets the CD47 immune checkpoint pathway. ALX148 is currently being evaluated in multiple Phase 1 and Phase 2 clinical trials for the treatment of various types of cancer, including solid tumors and hematologic malignancies. The company is also developing other immune checkpoint inhibitors and bispecific antibodies for the treatment of cancer. Alx Oncology Holdings was founded in 2015 and is headquartered in Burlingame, California.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X